Fibrinolysis in Trauma: “Myth,” “Reality,” or “Something in Between”

Abstract

The emphasis on fibrinolysis as an important contributor to trauma-induced coagulopathy (TIC) has led to a debate regarding the relative clinical significance of fibrinolysis in the setting of trauma. The debate has centered on two camps. The one camp defines fibrinolysis in trauma by standard coagulation tests as well as fibrin split products, D-dimers, and plasmin/antiplasmin levels. This camp favors a more liberal use of tranexamic acid and attributes more significance to hyperfibrinolysis in TIC. The other camp favors a definition of fibrinolysis based on the viscoelastic tests (VET), rotational thromboelastometry (ROTEM), and thromboelastography (TEG). These whole blood assays define hyperfibrinolysis at a higher threshold than plasma-based tests. Therefore, this VET camp reserves antifibrinolytic treatment for patients who demonstrate severe coagulopathy associated with hyperfibrinolysis. This bimodal attribution of the clinical relevance of fibrinolysis in trauma suggests that there may be an underlying “Myth” of the concept of TIC that was historically defined by plasma-based tests and a future “Reality” of the concept of TIC that is grounded on an understanding of TIC based on a VET-defined “fibrinolytic spectrum” of TIC. This narrative review explores this “Myth” and “Reality” of fibrinolysis in TIC and proposes a direction that will allow a “Future” interpretation of TIC that incorporates both the past “Myth” and present “Reality” of fibrinolysis TIC.

Keywords

fibrinolysis - trauma-induced coagulopathy - tranexamic acid - thromboelastography - rotational thromboelastometry - fibrinolytic spectrum - fibrinolytic shutdown - tissue injury phenotype - hyperfibrinolysis - hemorrhagic phenotype - activated protein C

• References

• 1 Ratnoff OD. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol 1969; 10: 145-227
• 2 Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med 2012; 40 (9) 2704-2708
• 3 Gando S. Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path. J Trauma 2009; 67 (2) 381-383
• 4 Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?. Ann Surg 2007; 245 (5) 812-818
• 5 Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54 (6) 1127-1130
• 6 Shakur H, Roberts I, Bautista R , et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734): 23-32
• 7 Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it?. J Trauma Acute Care Surg 2013; 74 (6) 1575-1586
• 8 Cap A, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia 2015; 70 (Suppl. 01) 96-101 , e32–e34
• 9 Campbell JE, Aden JK, Cap AP. Acute traumatic coagulopathy: Whole blood thrombelastography measures the tip of the iceberg. J Trauma Acute Care Surg 2015; 78 (5) 955-961
• 10 Campbell JE, Meledeo MA, Cap AP. Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy. PLoS One 2014; 9 (6) e99181
• 11 Harvin JA, Peirce CA, Mims MM , et al. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg 2015; 78 (5) 905-909 , discussion 909–911
• 12 Valle EJ, Allen CJ, Van Haren RM , et al. Do all trauma patients benefit from tranexamic acid?. J Trauma Acute Care Surg 2014; 76 (6) 1373-1378
• 13 Cotton BA, Harvin JA, Kostousouv V , et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73 (2) 365-370 , discussion 370
• 14 Gando S, Hayakawa M. Pathophysiology of trauma-Induced coagulopathy and management of critical bleeding requiring massive transfusion. Semin Thromb Hemost 2016; 42 (2) 155-165
• 15 Hess JR, Brohi K, Dutton RP , et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65 (4) 748-754
• 16 Gando S, Wada H, Thachil J ; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH). Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost 2013; 11 (5) 826-835
• 17 Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood 2016; 128 (8) 1043-1049
• 18 Dobson GP, Letson HL, Sharma R, Sheppard FR, Cap AP. Mechanisms of early trauma-induced coagulopathy: the clot thickens or not?. J Trauma Acute Care Surg 2015; 79 (2) 301-309
• 19 Ostrowski SR, Sørensen AM, Larsen CF, Johansson PI. Thrombelastography and biomarker profiles in acute coagulopathy of trauma: a prospective study. Scand J Trauma Resusc Emerg Med 2011; 19: 64
• 20 Johansson PI, Ostrowski SR. Acute coagulopathy of trauma: balancing progressive catecholamine induced endothelial activation and damage by fluid phase anticoagulation. Med Hypotheses 2010; 75 (6) 564-567
• 21 Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care 2015; 19: 72
• 22 Johansson PI, Stensballe J, Rosenberg I, Hilsløv TL, Jørgensen L, Secher NH. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 2007; 47 (4) 593-598
• 23 Frith D, Goslings JC, Gaarder C , et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010; 8 (9) 1919-1925
• 24 Maegele M. The coagulopathy of trauma. Eur J Trauma Emerg Surg 2014; 40 (2) 113-126
• 25 Cap A, Hunt B. Acute traumatic coagulopathy. Curr Opin Crit Care 2014; 20 (6) 638-645
• 26 Howard BM, Kornblith LZ, Cheung CK , et al. Inducing acute traumatic coagulopathy in vitro: the effects of activated protein C on healthy human whole blood. PLoS One 2016; 11 (3) e0150930
• 27 Cohen MJ, Call M, Nelson M , et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2012; 255 (2) 379-385
• 28 Johansson PI, Sørensen AM, Perner A , et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care 2011; 15 (6, R272): R272
• 29 Cohen MJ, Kutcher M, Redick B , et al; PROMMTT Study Group. Clinical and mechanistic drivers of acute traumatic coagulopathy. J Trauma Acute Care Surg 2013; 75 (1, Suppl 1): S40-S47
• 30 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 cross activation. Blood 2005; 105 (8) 3178-3184
• 31 Sawamura A, Hayakawa M, Gando S , et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009; 124 (5) 608-613
• 32 Oshiro A, Yanagida Y, Gando S, Henzan N, Takahashi I, Makise H. Hemostasis during the early stages of trauma: comparison with disseminated intravascular coagulation. Crit Care 2014; 18 (2) R61
• 33 Chapman MP, Moore EE, Moore HB , et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016; 80 (1) 16-23 , discussion 23–25
• 34 Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg 2011; 254 (1) 10-19
• 35 Moore HB, Moore EE, Gonzalez E , et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77 (6) 811-817 , discussion 817
• 36 Bluth MH, Kashuk JL. Mechanistic links in trauma-induced coagulopathy: a tale of two cities. Ann Surg 2011; 254 (1) 20-21
• 37 Schlimp CJ, Voelckel W, Inaba K, Maegele M, Schöchl H. Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/- fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scand J Trauma Resusc Emerg Med 2013; 21: 74
• 38 Collins PW, Solomon C, Sutor K , et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth 2014; 113 (4) 585-595
• 39 Kashuk JL, Moore EE, Sawyer M , et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010; 252 (3) 434-442 , discussion 443–444
• 40 Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 2006; 60 (6, Suppl): S51-S58
• 41 White NJ. Mechanisms of trauma-induced coagulopathy. Hematology (Am Soc Hematol Educ Program) 2013; 2013 (13) 660-663
• 42 Willoughby ML. A puerperal haemorrhagic state due to a henarin-like anticoagulant. J Clin Pathol 1963; 16: 108-111
• 43 Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254 (2) 194-200
• 44 Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg 2012; 73 (1) 60-66
• 45 Johansson PI, Henriksen HH, Stensballe J , et al. Traumatic endotheliopathy: a prospective observational study of 424 severely injured patients. Ann Surg 2017; 265 (3) 597-603
• 46 Rizoli S, Nascimento Jr B, Key N , et al. Disseminated intravascular coagulopathy in the first 24 hours after trauma: the association between ISTH score and anatomopathologic evidence. J Trauma 2011; 71 (5, Suppl 1): S441-S447
• 47 Vincent JL, De Backer D. Does disseminated intravascular coagulation lead to multiple organ failure?. Crit Care Clin 2005; 21 (3) 469-477
• 48 Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006; 4: 4
• 49 Biemond BJ, Levi M, Ten Cate H , et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88 (5) 587-594
• 50 van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72 (5) 1467-1473
• 51 Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75 (6) 902-907
• 52 Asakura H, Ontachi Y, Mizutani T , et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29 (6) 1164-1168
• 53 Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009; 22 (1) 129-136
• 54 Holley AD, Reade MC. The ‘procoagulopathy’ of trauma: too much, too late?. Curr Opin Crit Care 2013; 19 (6) 578-586
• 55 Pusateri AE, Weiskopf RB, Bebarta V , et al; US DoD Hemorrhage and Resuscitation Research and Development Steering Committee. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock 2013; 39 (2) 121-126
• 56 Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 2012; 147 (2) 113-119
• 57 Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg 2013; 148 (3) 218-225
• 58 MacDonald SG, Luddington RJ. Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost 2010; 36 (7) 712-722
• 59 Gruen RL, Jacobs IG, Reade MC ; PATCH-Trauma study. Trauma and tranexamic acid. Med J Aust 2013; 199 (5) 310-311
• 60 Rossaint R, Bouillon B, Cerny V , et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20: 100
• 61 Mutch N, Booth N. Plasmin-antiplasmin system. In: Gonzalez E, Moore H, Moore E, , eds. Trauma Induced Coagulopathy. Switzerland: Springer International Publishing; 2016: 31-51
• 62 Medcalf RL. The traumatic side of fibrinolysis. Blood 2015; 125 (16) 2457-2458
• 63 Hijazi N, Abu Fanne R, Abramovitch R , et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 2015; 125 (16) 2558-2567
• 64 Inaba K, Rizoli S, Veigas PV , et al; Viscoelastic Testing in Trauma Consensus Panel. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: report of the panel. J Trauma Acute Care Surg 2015; 78 (6) 1220-1229
• 65 Schöchl H, Voelckel W, Grassetto A, Schlimp CJ. Practical application of point-of-care coagulation testing to guide treatment decisions in trauma. J Trauma Acute Care Surg 2013; 74 (6) 1587-1598
• 66 Holcomb JB, Minei KM, Scerbo ML , et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256 (3) 476-486
• 67 Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol 2014; 27 (2) 212-218
• 68 Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and thromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45
• 69 Kashuk JL, Moore EE, Sawyer M , et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg 2010; 251 (4) 604-614
• 70 Schöchl H, Maegele M, Voelckel W. Fixed ratio versus goal-directed therapy in trauma. Curr Opin Anaesthesiol 2016; 29 (2) 234-244
• 71 Harr JN, Moore EE, Ghasabyan A , et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 2013; 39 (1) 45-49
• 72 Holcomb JB, Tilley BC, Baraniuk S , et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313 (5) 471-482
• 73 Theusinger OM, Stein P, Levy JH. Point of care and factor concentrate-based coagulation algorithms. Transfus Med Hemother 2015; 42 (2) 115-121
• 74 Gonzalez E, Moore EE, Moore HB , et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 2016; 263 (6) 1051-1059
• 75 Solomon C, Schöchl H, Ranucci M, Schlimp CJ. Can the viscoelastic parameter α-angle distinguish fibrinogen from platelet deficiency and guide fibrinogen supplementation?. Anesth Analg 2015; 121 (2) 289-301
• 76 McCurdy MT, Liew-Spilger A, Walsh M. Mortality and ratio of blood products used in patients with sever. e trauma. (Letter). JAMA 2015; 313 (20) 2077-2078
• 77 Moore HB, Moore EE, Gonzalez E. Mortality and ratio of blood products used in patients with severe traum. a. (Letter). JAMA 2015; 313 (20) 2077
• 78 Moore EE, Chin TL, Chapman MC , et al. Plasma first in the field for postinjury hemorrhagic shock. Shock 2014; 41 (Suppl. 01) 35-38
• 79 Moore HB, Moore EE, Morton AP , et al. Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation. J Trauma Acute Care Surg 2015; 79 (6) 897-903 , discussion 903–904
• 80 Moore HB, Moore EE, Chapman MP , et al. Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients. J Thromb Haemost 2015; 13 (10) 1878-1887
• 81 Wohlauer MV, Moore EE, Thomas S , et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg 2012; 214 (5) 739-746
• 82 Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg 2015; 261 (2) 390-394
• 83 Wafaisade A, Lefering R, Bouillon B, Böhmer AB, Gäßler M, Ruppert M ; TraumaRegister DGU. Prehospital administration of tranexamic acid in trauma patients. Crit Care 2016; 20 (1) 143
• 84 Moore HB, Moore EE, Liras IN , et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 2016; 222 (4) 347-355
• 85 Ausset S, Glassberg E, Nadler R , et al. Tranexamic acid as part of remote damage-control resuscitation in the prehospital setting: A critical appraisal of the medical literature and available alternatives. J Trauma Acute Care Surg 2015; 78 (6, Suppl 1): S70-S75
• 86 Moore H, Moore E, Gonzalez E. Fibrinolysis. In: Gonzalez E, Moore H, Moore E, , eds. Trauma Induced Coagulopathy. Switzerland: Springer International Publishing; 2016: 135-147
• 87 Moore EE, Moore HB, Gonzalez E, Sauaia A, Banerjee A, Silliman CC. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion 2016; 56 (Suppl. 02) S110-S114
• 88 Chakrabarti R, Hocking ED, Fearnley GR. Reaction pattern to three stresses--electroplexy, surgery, and myocardial infarction--of fibrinolysis and plasma fibrinogen. J Clin Pathol 1969; 22 (6) 659-662
• 89 Griffiths NJ. Factors affecting the fibrinolytic response to surgery. Ann R Coll Surg Engl 1979; 61 (1) 12-16
• 90 Yukizawa Y, Inaba Y, Watanabe S , et al. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 2012; 83 (1) 14-21
• 91 Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358 (8) 771-783
• 92 Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg 1969; 98 (1) 31-34
• 93 Kang YG, Martin DJ, Marquez J , et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985; 64 (9) 888-896
• 94 Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23 (11) 1835-1842
• 95 Ostrowski SR, Berg RM, Windeløv NA , et al. Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers. PLoS One 2013; 8 (3) e59368
• 96 Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3 (1) 35-56
• 97 Ogston D, Ogston CM, Ratnoff OD, Forbes CD. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest 1969; 48 (10) 1786-1801
• 98 Zufferey PJ, Miquet M, Quenet S , et al; Tranexamic Acid in Hip-Fracture Surgery (THIF) Study. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth 2010; 104 (1) 23-30
• 99 Kluft C, Verheijen JH, Jie AF , et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45 (7) 605-610
• 100 Kassis J, Hirsh J, Podor TJ. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Blood 1992; 80 (7) 1758-1764
• 101 Castellino FJ, Chapman MP, Donahue DL , et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. J Trauma Acute Care Surg 2014; 76 (5) 1169-1176
• 102 Sashindranath M, Sales E, Daglas M , et al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012; 135 (Pt 11): 3251-3264
• 103 Chapman MP, Moore EE, Ramos CR , et al. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 2013; 75 (6) 961-967 , discussion 967
• 104 Schöchl H, Voelckel W, Maegele M, Solomon C. Trauma-associated hyperfibrinolysis. Hamostaseologie 2012; 32 (1) 22-27
• 105 Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thromboelastometry. J Trauma 2009; 67 (1) 125-131
• 106 Theusinger OM, Wanner GA, Emmert MY , et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113 (5) 1003-1012
• 107 Tapia NM, Chang A, Norman M , et al. TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients. J Trauma Acute Care Surg 2013; 74 (2) 378-385 , discussion 385–386
• 108 Li R, Elmongy H, Sims C, Diamond SL. Ex vivo recapitulation of trauma-induced coagulopathy and preliminary assessment of trauma patient platelet function under flow using microfluidic technology. J Trauma Acute Care Surg 2016; 80 (3) 440-449
• 109 Raza I, Davenport R, Rourke C , et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11 (2) 307-314
• 110 Ramos CR, Moore EE, Manco-Johnson ML, Silliman CC, Chapman MC, Banerjee A. The incidence and magnitude of fibrinolytic activation in trauma patients: a rebuttal. J Thromb Haemost 2013; 11 (7) 1435-1437
• 111 Larsen OH, Fenger-Eriksen C, Ingerslev J, Sørensen B. Improved point-of-care identification of hyperfibrinolysis is needed. Thromb Res 2012; 130 (4) 690-691
• 112 Hunt BJ, Raza I, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients: a reply to a rebuttal. J Thromb Haemost 2013; 11 (7) 1437-1438
• 113 Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. Blood 2014; 124 (20) 3052-3058
• 114 Schöchl H, Maegele M, Solomon C, Görlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 2012; 20: 15
• 115 Branco BC, Inaba K, Ives C , et al. Thromboelastogram evaluation of the impact of hypercoagulability in trauma patients. Shock 2014; 41 (3) 200-207
• 116 Schlimp CJ, Solomon C, Ranucci M, Hochleitner G, Redl H, Schöchl H. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry. Anesth Analg 2014; 118 (2) 269-276
• 117 Johansson PI, Sørensen AM, Larsen CF , et al. Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets. Transfusion 2013; 53 (12) 3088-3099
• 118 Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg 2012; 72 (2) 428-436
• 119 Kutcher ME, Redick BJ, McCreery RC , et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012; 73 (1) 13-19
• 120 Solomon C, Traintinger S, Ziegler B , et al. Platelet function following trauma. A multiple electrode aggregometry study. Thromb Haemost 2011; 106 (2) 322-330
• 121 Chandler WL. Procoagulant activity in trauma patients. Am J Clin Pathol 2010; 134 (1) 90-96
• 122 Adamzik M, Eggmann M, Frey UH , et al. Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care 2010; 14 (5) R178
• 123 Ostrowski SR, Haase N, Müller RB , et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care 2015; 19: 191